|Titre :||Options for the use of methadone in the treatment of drug dependence|
|Auteurs :||OMS / WHO|
|Type de document :||Rapport|
|Editeur :||Genève : OMS / WHO, 1989|
|Format :||13 p. / tab.|
|Discipline :||SAN (Santé publique / Public health)|
Thésaurus TOXIBASESUBSTITUTION ; METHADONE ; PROGRAMME ; TRAITEMENT DE MAINTENANCE ; POLITIQUE
The purpose of this meeting was to review the role of methadone as a substitution drug for the treatment and management of opioid dependence. More data are available for methadone than any other substitution drug though there are problems and omissions in the literature that highlight the need for further research on this important issue. This meeting reviewed the experience with methadone in countries drawn from four continents. Although much is known regarding the effect of methadone maintenance on individuals, little is known about the effect of this treatment on communities. The ethical aspects of methadone maintenance remain controversial.
The meeting took place in the context of the pandemic of HIV infection which has already resulted in substantial proportions of IDUs becoming infected in Europe, America and parts of Asia. An important task is to prevent HIV infection from spreading further to uninfected IDU and new recruits to drug use. Individual countries will need to consider the importance of containing HIV infection and preventing the spread of further drug use in the context of the size of their IDU population and the prevalence of HIV infection. Methadone maintenance can be a valuable treatment option and should therefore be considered as one of the range of services potentially contributing to the containment of HIV infection.
The possibility of protracted methadone maintenance may be an unappealing notion for some health professionals and policy planners. Nevertheless, this option may be preferable to cessation of treatment in light of the range of health consequences of relapse, including those associated with the risk of HIV infection. Health policy planners will need to balance the requirement for increased duration of treatment for individual IDUs with the need on public health grounds to provide equity of health care delivery.(Author's abstract)
|Domaine :||Drogues illicites / Illicit drugs|
|Refs biblio. :||7|